文章摘要

循环microRNA-95在前列腺癌早期精准诊断和预后判断中的作用

作者: 1肖春玲, 2朱进, 1王苏贵
1 徐州医科大学附属淮安医院泌尿外科,江苏 淮安 223002
2 苏州大学附属第二医院泌尿外科,江苏 苏州 215004
通讯: 王苏贵 Email: wangsugui107@163.com
DOI: 10.3978/j.issn.2095-6959.2019.12.005
基金: 江苏省“六大人才高峰”项目(2019-WSW-218);淮安市自然科学基金(HAB201730);徐州医科大学附属淮安医院科研基金(YK201506)。

摘要

目的:探讨循环microRNA(以下简称miR-95)在前列腺癌早期精准诊断和预后判断中的作用。方法:通过qPCR检测60例前列腺癌患者、60例前列腺增生患者及60例健康男性血清miR-95的相对表达水平,分析血清miR-95的相对表达水平与临床病理特征的关系,并构建受试者工作特征(receiver operating characters,ROC)曲线,分析血清miR-95对于前列腺癌诊断的敏感度和特异度。结果:前列腺癌患者血清miR-95的表达水平较前列腺增生及健康男性增高,差异有统计学意义(P<0.05),而前列腺增生患者血清miR-95的表达水平和健康男性中的表达无明显统计学差异(P>0.05)。血清miR-95表达水平与前列腺癌临床病理分期、Gleason评分及骨转移显著相关(P<0.05);与年龄、前列腺特异性抗原水平无关(P>0.05)。ROC曲线显示miR-95能够较好的区分前列腺癌与前列腺增生及健康男性,曲线下面积分别为0.826(95%CI:0.792~0.918)和0.808(95%CI:0.745~0.919)。结论:miR-95在前列腺癌患者血清中高表达,与前列腺癌进展有关,有望作前列腺癌早期精准诊断和预后的标志物。
关键词: miR-95;血清;前列腺癌

Role of circulating microRNA-95 in early accurate diagnosis and prognosis of prostate cancer

Authors: 1XIAO Chunling, 2ZHU Jin, 1WANG Sugui
1 Department of Urology, Huai’an Hospital Affiliated of Xuzhou Medical College, Huai’an Jiangsu 223002
2 Department of Urology, the Second Affiliated Hospital of Soochow University, Suzhou Jiangsu 215004, China

CorrespondingAuthor: WANG Sugui Email: wangsugui107@163.com

DOI: 10.3978/j.issn.2095-6959.2019.12.005

Foundation: This work was supported by the Six Talents Peak Programs in Jiangsu Province (2019-WSW-218), Natural Science Foundation of Huai’an (HAB201730) and Scientific Research Project of Huaian Hospital Affiliated to Xuzhou Medical University (YK201506)

Abstract

Objective: To investigate the role of circulating microRNA-95 in early accurate diagnosis and prognosis of prostate cancer. Methods: qPCR was used to detect the relative expression level of serum microRNA-95 in 60 patients with prostate cancer, 60 patients with benign prostatic hyperplasia and 60 healthy men. The relationship between the relative expression level of serum microRNA-95 and clinicopathological characteristics was analyzed. The ROC curve was constructed to analyze the sensitivity and specificity of serum microRNA-95 in the diagnosis of prostate cancer. Results: The expression level of serum microRNA-95 in prostate cancer patients was higher than that in benign prostatic hyperplasia and healthy men (P<0.05), but there was no significant difference in the expression level of serum microRNA-95 between benign prostatic hyperplasia patients and healthy men (P>0.05). Serum level of microRNA-95 was significantly correlated with clinical pathological stage, Gleason score and bone metastasis of prostate cancer (P<0.05), but not with age and prostate specific antigen (P>0.05). ROC curve showed that microRNA-95 could differentiate prostate cancer from benign prostatic hyperplasia and healthy males. The area under the curve was 0.826 (95% CI: 0.792–0.918) and 0.808 (95% CI: 0.745–0.919), respectively. Conclusion: The high expression of microRNA-95 in the serum of prostate cancer patients is related to the progression of prostate cancer, and it is expected to be a marker of early accurate diagnosis and prognosis of prostate cancer.
Keywords: microRNA-95; serum; prostate cancer